Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
Title:
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
Author:
Tanaka, Kazuki Adams, Brigitte Aris, Alvaro Madrid Fujita, Naoya Ogawa, Masayo Ortiz, Stephan Vallee, Marc Greenbaum, Larry A.